Device Trial Radar · NCT06824987
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
Mar 5, 2025
Primary completion
Oct 4, 2027
Study completion Oct 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Conditions
- APOL1-Mediated Kidney Disease
Interventions
AZD2373-Arm 1Combination product
Accessorized Pre-Filled Syringe (Solution for injection)
AZD2373-Arm 2Combination product
Accessorized Pre-Filled Syringe (Solution for injection)
PlaceboCombination product
Accessorized Pre-Filled Syringe (Solution for injection).
APOL1 Genotyping Clinical Trial AssayDevice
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in Urine Albumin-Creatinine Ratio (UACR)Time frame: From Baseline at Week 30
Locations
96 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Alabaster, Alabama
Research Site
Birmingham, Alabama
Research Site
Irondale, Alabama
93 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.